Suicidal CrisisRBSCPNCT07740356
Prevalence of Brief Suicidal Crisis in Psychiatric Settings
An observational study of Suicidal Crisis and Psychiatric Disorder, run by University Hospital, Clermont-Ferrand at 1 site in France.
Trial summary
France is among the countries with one of the highest suicide rates in the world, far above those of its neighboring countries [Wasserman et al., 2012]. Suicide is the second leading cause of death among 15-24-year-olds, just after road traffic accidents, and the leading cause of death among 25-34-year-olds. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Suicidal Crisis, Psychiatric Disorder
- How many people
- 150 participants
- Where
- 1 siteFrance
- Study dates
- 1 Sep 2026to 31 Dec 2026
- How long will I take part?
- 1 Day
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: patient consulting the psychiatrist in his/her office during the recruitment period
Who may be able to join
- Any adult patient consulting the psychiatrist in his/her office during the recruitment period, regardless of the reason for the consultation, and who has given consent to participate in this study.
Who cannot join
- Minor patients, or patients who refuse to participate in the study.
- Patients who have already completed the self-administered questionnaires previously (e.g., a second consultation within the same week).
- Patients unable to understand and complete the self-administered questionnaires (cognitive impairment, difficulty understanding French, etc.).
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
France1 site, 1 recruiting
- Recruiting
CHU de Clermont-ferrand
Clermont-Ferrand, 63000
About this study
France is among the countries with one of the highest suicide rates in the world, far above those of its neighboring countries [Wasserman et al., 2012]. Suicide is the second leading cause of death among 15-24-year-olds, just after road traffic accidents, and the leading cause of death among 25-34-year-olds. Current models emphasize the variability of suicidal trajectories and the possible fluctuation in the duration of suicidal crises: for some individuals, the crisis evolves rapidly and explosively (brief), whereas for others, distress becomes more chronic, often in connection with underlying psychiatric disorders [Stanley, Brodsky, and Monahan, 2023]. In this context, the concept of a 'brief suicidal crisis' is an emerging one in psychiatry. It is characterized by an acute phase of psychological vulnerability, during which the main risk is progression to suicidal behavior, but it remains a temporary and reversible psychic crisis (lasting less than 24 hours). The crisis state is marked by a sudden inability to mobilize one's usual coping resources in the face of difficulties, making the individual highly vulnerable. Nevertheless, this concept has been little described, and a better assessment seems desirable, particularly in populations consulting a psychiatrist. Indeed, around 25% of people who die by suicide had consulted a psychiatrist in the month before their death [Luoma et al., 2002], yet few data are available on this topic.
Primary objective is to assess the prevalence of brief suicidal crisis episodes (lasting less than 24 hours) over the past 12 months among patients attending outpatient psychiatric care and within a sample of patients from a population catchment area in the Clermont-Ferrand region.
Read the detailed description
Only one visit to estimate the 12-month prevalence of brief suicidal crises, defined as lasting less than 24 hours, among patients seen in outpatient psychiatric practice and in a population-based sample from the Clermont-Ferrand catchment area.
Secondary objectives are to describe the study population and explore factors potentially associated with brief suicidal crises, including age and sex; to assess psychological pain during brief suicidal crises; to estimate the 12-month prevalence of suicidal crises lasting more than 24 hours; to assess psychological pain during suicidal crises lasting more than 24 hours.
- Conditions
- Suicidal Crisis, Psychiatric Disorder
- Keywords
- suicidal crisis
- Medical subject headings
- Mental Disorders
What is being measured
The primary outcome is the main question the study is designed to answer.
Risk score of brief suicidal crisis
Risque suicidaire de Ducher a (aRSD) scale score for brief suicidal crises. Minimum score 0 maximum score 10 . highter score mean worse outcome
Measured: Day 1
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted31 Jul 2026
- Study start1 Sep 2026 (estimated)
- Primary completion31 Dec 2026 (estimated)
- Study completion31 Dec 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Suicidal CrisisStudies of the same condition, open and under way.
- More trials run by University Hospital, Clermont-FerrandThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Ecologic or community
- Time perspective
- Prospective
- Enrolment
- 150 participants (estimated)
- Target duration
- 1 Day
Sponsor and investigators
- Lead sponsor
- University Hospital, Clermont-Ferrand
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07740356
- Sponsor's protocol ID
- 2025-CF568
- Acronym
- RBSCP
- Status last verified
- Jul 2026
- First submitted
- 27 Jul 2026
- Last updated
- 31 Jul 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 31 Jul 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Prevalence of Brief Suicidal Crisis in Psychiatric Settings
- ClinicalTrials.gov ID
- NCT07740356
- Acronym / sponsor ID
- RBSCP / 2025-CF568
- Conditions
- Suicidal Crisis, Psychiatric Disorder
- Keywords
- suicidal crisis
- Study type
- Observational
- Recruitment status
- Recruiting
- Enrolment
- 150 participants (estimated)
- Lead sponsor
- University Hospital, Clermont-FerrandUniversity, hospital or other
- Study start
- 1 Sep 2026 (estimated)
- Primary completion
- 31 Dec 2026 (estimated)
- Study completion
- 31 Dec 2026 (estimated)
- First posted
- 31 Jul 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
France is among the countries with one of the highest suicide rates in the world, far above those of its neighboring countries [Wasserman et al., 2012]. Suicide is the second leading cause of death among 15-24-year-olds, just after road traffic accidents, and the leading cause of death among 25-34-year-olds. Current models emphasize the variability of suicidal trajectories and the possible fluctuation in the duration of suicidal crises: for some individuals, the crisis evolves rapidly and explosively (brief), whereas for others, distress becomes more chronic, often in connection with underlying psychiatric disorders [Stanley, Brodsky, and Monahan, 2023]. In this context, the concept of a 'brief suicidal crisis' is an emerging one in psychiatry. It is characterized by an acute phase of psychological vulnerability, during which the main risk is progression to suicidal behavior, but it remains a temporary and reversible psychic crisis (lasting less than 24 hours). The crisis state is marked by a sudden inability to mobilize one's usual coping resources in the face of difficulties, making the individual highly vulnerable. Nevertheless, this concept has been little described, and a better assessment seems desirable, particularly in populations consulting a psychiatrist. Indeed, around 25% of people who die by suicide had consulted a psychiatrist in the month before their death [Luoma et al., 2002], yet few data are available on this topic.
Primary objective is to assess the prevalence of brief suicidal crisis episodes (lasting less than 24 hours) over the past 12 months among patients attending outpatient psychiatric care and within a sample of patients from a population catchment area in the Clermont-Ferrand region.
Detailed description
Only one visit to estimate the 12-month prevalence of brief suicidal crises, defined as lasting less than 24 hours, among patients seen in outpatient psychiatric practice and in a population-based sample from the Clermont-Ferrand catchment area.
Secondary objectives are to describe the study population and explore factors potentially associated with brief suicidal crises, including age and sex; to assess psychological pain during brief suicidal crises; to estimate the 12-month prevalence of suicidal crises lasting more than 24 hours; to assess psychological pain during suicidal crises lasting more than 24 hours.
Study design
- Observational model
- Ecologic or community
- Time perspective
- Prospective
- Target follow-up
- 1 Day
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- patient consulting the psychiatrist in his/her office during the recruitment period
Key inclusion criteria (1 listed)
- Any adult patient consulting the psychiatrist in his/her office during the recruitment period, regardless of the reason for the consultation, and who has given consent to participate in this study.
Key exclusion criteria (3 listed)
- Minor patients, or patients who refuse to participate in the study.
- Patients who have already completed the self-administered questionnaires previously (e.g., a second consultation within the same week).
- Patients unable to understand and complete the self-administered questionnaires (cognitive impairment, difficulty understanding French, etc.).
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Risk score of brief suicidal crisis
Time frame: Day 1
Risque suicidaire de Ducher a (aRSD) scale score for brief suicidal crises. Minimum score 0 maximum score 10 . highter score mean worse outcome
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 31 Jul 2026.
- Individual participant dataSharing planned: No
Related trials for Suicidal Crisis
Recruiting
Preventing Suicidal Behavior With Diverse High-Risk Youth in Acute Care Settings
Suicide, Attempted, Suicide Ideation
Not yet recruitingPhase 2
Intravenous Ketamine for Acute Suicidal Crisis and Psychiatric Hospital Length of Stay
Suicidal Ideation, Suicidal Behavior
RecruitingPhase 2
Alleviating Suicidality by Combining Psychotherapy and IM Ketamine for Rapid Treatment in the Emergency Department
Suicidal Ideation
Enrolling by invitation
Efficacy, Effectiveness, and Implementation of Jaspr Health in Emergency Department- Part B
Suicidal Ideation, Suicide Attempt
RecruitingPhase 2/3
Ketamine & Crisis Response Plan for Suicidal Ideation in the ED
Suicide
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Suicidal Crisis and Psychiatric Disorder, run by University Hospital, Clermont-Ferrand at 1 site in France.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 31 Jul 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in France. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Pierre-Michel LLORCA, prof (33473752124, pmllorca@chu-clermontferrand.fr), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Risk score of brief suicidal crisis (time frame: Day 1). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 31 Jul 2026.